I Ozola Zalite1, R Zykus2, M Francisco Gonzalez3, F Saygili4, A Pukitis5, S Gaujoux6, R M Charnley7, V Lyadov8. 1. Pauls Stradins Clinical University Hospital, Riga, Latvia. 2. Hospital of Lithuanian University of Health Sciences Kaunas, Lithuania. 3. Complexo Hospitalario Universitario de Ourense, Ourense, Spain. 4. Department of Gastroenterology Pamukkale University, Denizli, Turkey. 5. Pauls Stradins Clinical University Hospital, Riga, Latvia; Faculty of Medicine, University of Latvia, Riga, Latvia. 6. Department of Digestive and Endocrine Surgery, Cochin Hospital, APHP, Paris, France; Faculté de Medecine Paris Descartes, Université Paris Descartes, Sorbonne Paris Cité, France. 7. North East's Hepato-Pancreato-Biliary Centre at the Freeman Hospital, Newcastle, United Kingdom. 8. Department of Surgical Oncology, Medical and Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russia. Electronic address: vlyadov@gmail.com.
Abstract
BACKGROUND/ OBJECTIVES: Cachexia affects ∼ 80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. METHODS: The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database until December 2013. After identifying relevant titles, abstracts were read and eligible articles data retrieved on preformatted sheets. The prevalence and impact of sarcopenia/cachexia on survival was evaluated. RESULTS: In total 1145 articles were retrieved, only 10 were eligible. Definitions of cachexia and sarcopenia were heterogeneous. In patients with normal weight (BMI 18.5-24.9 kg/m(2)) the prevalence of sarcopenia ranged from 29.7 to 65%. In overweight or obese patients (BMI >25 kg/m(2)) were 16.2%-67%. Sarcopenia alone was not demonstrated to be an independent factor of decreased survival, although obese sarcopenic patients were shown to have significantly worse survival in two studies. CONCLUSIONS: Impact of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma is currently understudied in the available literature. Definitive association between cachexia and survival cannot be drawn from available studies, although weight loss and sarcopenic obesity might be considered as poor prognostic factors. Further prospective trials utilizing the consensus definition of cachexia and including other confounding factors are needed to investigate the impact of cachexia and sarcopenia on survival in pancreatic adenocarcinoma.
BACKGROUND/ OBJECTIVES:Cachexia affects ∼ 80% of pancreatic cancerpatients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. METHODS: The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database until December 2013. After identifying relevant titles, abstracts were read and eligible articles data retrieved on preformatted sheets. The prevalence and impact of sarcopenia/cachexia on survival was evaluated. RESULTS: In total 1145 articles were retrieved, only 10 were eligible. Definitions of cachexia and sarcopenia were heterogeneous. In patients with normal weight (BMI 18.5-24.9 kg/m(2)) the prevalence of sarcopenia ranged from 29.7 to 65%. In overweight or obesepatients (BMI >25 kg/m(2)) were 16.2%-67%. Sarcopenia alone was not demonstrated to be an independent factor of decreased survival, although obese sarcopenicpatients were shown to have significantly worse survival in two studies. CONCLUSIONS: Impact of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma is currently understudied in the available literature. Definitive association between cachexia and survival cannot be drawn from available studies, although weight loss and sarcopenic obesity might be considered as poor prognostic factors. Further prospective trials utilizing the consensus definition of cachexia and including other confounding factors are needed to investigate the impact of cachexia and sarcopenia on survival in pancreatic adenocarcinoma.
Authors: B Laquente; A Calsina-Berna; A Carmona-Bayonas; P Jiménez-Fonseca; I Peiró; A Carrato Journal: Clin Transl Oncol Date: 2017-06-13 Impact factor: 3.405
Authors: O Köstek; N C Demircan; A Gökyer; A Küçükarda; B S Sunal; M B Hacıoğlu; H Eslame; S Solak; E Yılmaz; S Uzunoğlu; N Tunçbilek; I Çiçin; B Erdoğan Journal: Clin Transl Oncol Date: 2019-03-28 Impact factor: 3.405
Authors: Stephen P Pereira; Lucy Oldfield; Alexander Ney; Phil A Hart; Margaret G Keane; Stephen J Pandol; Debiao Li; William Greenhalf; Christie Y Jeon; Eugene J Koay; Christopher V Almario; Christopher Halloran; Anne Marie Lennon; Eithne Costello Journal: Lancet Gastroenterol Hepatol Date: 2020-03-02
Authors: Simone Gärtner; Janine Krüger; Ali A Aghdassi; Antje Steveling; Peter Simon; Markus M Lerch; Julia Mayerle Journal: Gastrointest Tumors Date: 2016-01-08
Authors: Jeffrey A Meyerhardt; Candyce H Kroenke; Carla M Prado; Marilyn L Kwan; Adrienne Castillo; Erin Weltzien; Elizabeth M Cespedes Feliciano; Jingjie Xiao; Bette J Caan Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-16 Impact factor: 4.254
Authors: Loveena Sreedharan; Bhaskar Kumar; Anna Jewell; Paul Banim; Andreas Koulouris; Andrew R Hart Journal: Frontline Gastroenterol Date: 2018-10-09
Authors: Marta Sandini; Manuel Patino; Cristina R Ferrone; Carlos A Alvarez-Pérez; Kim C Honselmann; Salvatore Paiella; Matteo Catania; Luca Riva; Giorgia Tedesco; Raffaella Casolino; Alessandra Auriemma; Maria C Salandini; Giulia Carrara; Giulia Cristel; Anna Damascelli; Davide Ippolito; Mirko D'Onofrio; Keith D Lillemoe; Claudio Bassi; Marco Braga; Luca Gianotti; Dushyant Sahani; Carlos Fernández-Del Castillo Journal: JAMA Surg Date: 2018-09-01 Impact factor: 14.766
Authors: Laura Nemer; Somashekar G Krishna; Zarine K Shah; Darwin L Conwell; Zobeida Cruz-Monserrate; Mary Dillhoff; Denis C Guttridge; Alice Hinton; Andrei Manilchuk; Timothy M Pawlik; Carl R Schmidt; Erin E Talbert; Tanios Bekaii-Saab; Phil A Hart Journal: Pancreas Date: 2017-10 Impact factor: 3.327